◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

KYORIN Pharmaceutical Co., Ltd. (4569) Financial History

Name: KYORIN Pharmaceutical Co., Ltd. (4569) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-11

KYORIN Pharmaceutical Co., Ltd. (4569) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Tokyo, Japan with about 1,982 employees. Its market capitalization is roughly JPY 64 billion. In the fiscal year ended 2026-03-31, 4569 reported JPY 126.3B in revenue and JPY 3.4B in net income.

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells generic drugs in Japan and internationally. The company is also involved in drug discovery and licensing activities. It also offers infectious disease-related products; over-the-counter drug; and generic drugs.

Interactive charts & full statements →

4569 Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	JPY 126.3B	JPY 130.1B	JPY 119.5B	JPY 113.3B	—
Gross Profit	JPY 51.6B	JPY 59.5B	JPY 51.6B	JPY 50.2B	—
Operating Income (EBIT)	JPY 3.6B	JPY 12.6B	JPY 6.2B	JPY 5.1B	—
Net Income	JPY 3.4B	JPY 9.1B	JPY 5.5B	JPY 4.7B	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4569 Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(JPY 3.3B)	(JPY 3.0B)	(JPY 3.0B)	(JPY 3.0B)	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4569 Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	JPY 195.5B	JPY 193.6B	JPY 177.6B	JPY 176.0B	—
Total Liabilities	JPY 53.0B	JPY 57.3B	JPY 46.9B	JPY 50.6B	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 4569 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

4521 · Kaken Pharmaceutical Co., Ltd. — $151 billion
TEVA · Teva Pharmaceutical Industries Limited — ₪125 billion
4534 · Mochida Pharmaceutical Co., Ltd. — $114 billion
4559 · Zeria Pharmaceutical Co., Ltd. — $91 billion
4886 · ASKA Pharmaceutical Holdings Co.,Ltd. — $58 billion
4554 · Fuji Pharma Co., Ltd. — $48 billion
2196 · Shanghai Fosun Pharmaceutical (Group) Co., Ltd. — $46 billion
GALD · GALDERMA GROUP N — $40 billion

← 4568 All “0-9” companies 4574 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.